The Chemopreventive Agent α-Difluoromethylornithine Blocks Ki-ras-Dependent Tumor Formation and Specific Gene Expression in Caco-2 Cells

Molecular Carcinogenesis

Volumn 39, Issue 4, 2004, Pages 221-233

  Ignatenko, Natalia A ^a   Zhang, Hui ^a   Watts, George S ^b   Skovan, Bethany A ^a   Stringer, David E ^a   Gerner, Eugene W ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Caco 2 cells; Cx43; DFMO; Ki ras

Indexed keywords

ALPHA1 INTEGRIN; CONNEXIN 43; EFLORNITHINE; ENDOTHELIN 1; ENDOTHELIN 3; GAP JUNCTION PROTEIN; KALLIKREIN; LAMININ; ORNITHINE DECARBOXYLASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEINASE; SELENOPROTEIN; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COMMUNICATION; CELL MIGRATION; CELL STRAIN CACO 2; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; CYTOSKELETON; DNA MICROARRAY; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MOUSE; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE KI RAS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CACO-2 CELLS; CELL COMMUNICATION; CELL MOVEMENT; COLONIC NEOPLASMS; EFLORNITHINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENES, RAS; HUMANS; LAMININ; MICE; MICE, SCID; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORNITHINE DECARBOXYLASE; TRANSFECTION;

ANIMALIA;

EID: 1842481509     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.20008     Document Type: Article

References (60)

1. BosJL. ras oncogenes in human cancer: A review. Cancer Res 1989;49(17):4682-4689.
2. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of Ki-ras oncogenes during human colon tumorigenesis. Nature 1987;327(6120):298-303.
3. Powell SM, Petersen GM, Krush AJ, et al. Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 1993;329(27):1982-1987.
4. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene 1998;17(11 Reviews):1395-1413.
5. Sheng H, Shao J, Dubois RN. Ki-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1. Cancer Res 2001;61(6):2670-2675.
6. Taylor MT, Lawson KR, Ignatenko NA, et al. Sulindac sulfone inhibits Ki-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. Cancer Res 2000;60(23):6607-6610.
7. Shao J, Sheng H, DuBois RN. Peroxisome proliferator-activated receptors modulate Ki-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 2002;62(11): 3282-3288.
8. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993;260(5104):85-88.
9. Zhang X, Gaspard JP, Chung DC. Regulation of vascular endothelial growth factor by the Wnt and Ki-ras pathways in colonic neoplasia. Cancer Res 2001;61(16):6050-6054.
10. Nigro ND, Bull AW, Boyd ME. Inhibition of intestinal carcinogenesis in rats: Effect of difluoromethylornithine with piroxicam or fish oil. J Natl Cancer Inst 1986;77(6):1309-1313.
11. Pereira MA, Khoury MD. Prevention by chemopreventive agents of azoxymethane-induced foci of aberrant crypts in rat colon. Cancer Lett 1991;61(1):27-33.
12. Erdman SH, Ignatenko NA, Powell MB, et al. APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse. Carcinogenesis 1999;20(9): 1709-1713.
13. Heby O. Role of polyamines in the control of cell proliferation and differentiation. Differentiation 1981;19(1):1-20.
14. Tabor CW, Tabor H. Polyamines. Annu Rev Biochem 1984;53:749-790.
15. Janne J, Alhonen L, Leinonen P. Polyamines: From molecular biology to clinical applications. Ann Med 1991;23(3):241-259.
16. Igarashi K, Kashiwagi K. Polyamines: Mysterious modulators of cellular functions. Biochem Biophys Res Commun 2000;271(3):559-564.
17. Matsufuji S, Matsufuji T, Miyazaki Y, et al. Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme. Cell 1995;80(1):51-60.
18. Lux GD, Marton U, Baylin SB. Ornithine decarboxylase is important in intestinal mucosal maturation and recovery from injury in rats. Science 1980;210(4466):195-198.
19. McCormack SA, Johnson LR. Polyamines and cell migration. J Physiol Pharmacol 2001;52(3):327-349.
20. Sertich GJ, Glass JR, Fuller DJ, Gerner EW. Altered polyamine metabolism in Chinese hamster cells growing in a defined medium. J Cell Physiol 1986;127(1):114-120.
21. Watts GS, Futscher BW, Isett R, Gleason-Guzman M, Kunkel MW, Salmon SE. cDNA microarray analysis of multidrug resistance: Doxorubicin selection produces multiple defects in apoptosis signaling pathways. J Pharmacol Exp Ther 2001;299(2):434-441.
22. Crowley-Weber CL, Payne CM, Gleason-Guzman M, et al. Development and molecular characterization of HCT-116 cell lines resistant to the tumor promoter and multiple stress-inducer, deoxycholate. Carcinogenesis 2002;23(12):2063-2080.
23. Singh J, Kulkarni N, Kelloff G, Reddy BS. Modulation of azoxymethane-induced mutational activation of ras protooncogenes by chemopreventive agents in colon carcinogenesis. Carcinogenesis 1994;15(7):1317-1323.
24. Lawson KR, Ignatenko NA, Piazza GA, Cui H, Gerner EW. Influence of Ki-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine. Cancer Epidemiol Biomarkers Prev 2000;9(11):1155-1162.
25. Ignatenko NA, Babbar N, Mehta D, Casero RA, Jr., Gerner EW. Suppression of polyamine catabolism by activated Ki-ras in human colon cancer cells. Mol Carcinog 2003;39:91-102.
26. Komura J, Okada T, Ono T. Repression of transient expression by DNA methylation in transcribed regions of reporter genes introduced into cultured human cells. Biochim Biophys Acta 1995;1260(1):73-78.
27. Radford DM, Nakai H, Eddy RL, et al. Two chromosomal locations for human ornithine decarboxylase gene sequences and elevated expression in colorectal neoplasia. Cancer Res 1990;50(19):6146-6153.
28. Yamada KM, Miyamoto S. Integrin transmembrane signaling and cytoskeletal control. Curr Opin Cell Biol 1995;7(5):681-689.
29. Clark EA, Brugge JS. Integrins and signal transduction pathways: The road taken. Science 1995;268(5208):233-239.
30. Chipman JK, Mally A, Edwards GO. Disruption of gap junctions in toxicity and carcinogenicity. Toxicol Sci 2003;71(2):146-153.
31. Lorand L, Conrad SM. Transglutaminases. Mol Cell Biochem 1984;58(1-2):9-35.
32. Davies PJ, Chiocca EA, Basilion JP, Poddar S, Stein JP. Transglutaminases and their regulation: Implications for polyamine metabolism. Adv Exp Med Biol 1988;250:391-401.
33. Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. Understanding Ras: 'It ain't over 'til it's over'. Trends Cell Biol 2000;10(4):147-154.
34. Trainer DL, Kline T, McCabe FL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int J Cancer 1988;41(2):287-296.
35. Delage S, Chastre E, Empereur S, et al. Increased protein kinase C alpha expression in human colonic Caco-2 cells after insertion of human Ha-ras or polyoma virus middle T oncogenes. Cancer Res 1993;53(12):2762-2770.
36. Djelloul S, Forgue-Lafitte ME, Hermelin B, et al. Enterocyte differentiation is compatible with SV40 large T expression and loss of p53 function in human colonic Caco-2 cells. Status of the pRb1 and pRb2 tumor suppressor gene products. FEBS Lett 1997;406(3):234-242.
37. Elmore E, Stringer DE, Steele VE, Gerner EW, Redpath JL. Chemoprevention by difluoromethylornithine: Correlation of an in vitro human cell assay with human clinical data for biomarker modulation. Anticancer Res 2001;21(2A): 1163-1165.
38. Carbone PP, Douglas JA, Larson PO, et al. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine. Cancer Epidemiol Biomarkers Prev 1998;7(10):907-912.
39. Meyskens FL, Jr., Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 1999;5(5):945-951.
40. Poulin R, Lu L, Ackermann B, Bey P, Pegg AE. Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by alpha-difluoromethylornithine. Characterization of sequences at the inhibitor and coenzyme binding sites. J Biol Chem 1992;267(1):150-158.
41. Coleman CS, Stanley BA, Pegg AE. Effect of mutations at active site residues on the activity of ornithine decarboxylase and its inhibition by active site-directed irreversible inhibitors. J Biol Chem 1993; 268(33):24572-24579.
42. Grishin NV, Osterman AL, Brooks HB, Phillips MA, Goldsmith EJ. X-ray structure of ornithine decarboxylase from Trypanosoma brucei: The native structure and the structure in complex with alpha-difluoromethylornithine. Biochemistry 1999;38(46):15174-15184.
43. Schramm K, Krause K, Bittroff-Leben A, Goldin-Lang P, Thiel E, Kreuser ED. Activated Ki-ras is involved in regulation of integrin expression in human colon carcinoma cells. Int J Cancer 2000;87(2):155-164.
44. Vossmeyer D, Kaufmann C, Loster K, et al. The cytoplasmic domain of the alpha1 integrin subunit influences stress fiber formation via the conserved GFFKR motif. Exp Cell Res 2000;256(1):321-327.
45. Loster K, Vossmeyer D, Hofmann W, Reutter W, Danker K. alpha1 Integrin cytoplasmic domain is involved in focal adhesion formation via association with intracellular proteins. Biochem J 2001;356(Pt. 1):233-240.
46. Simon-Assmann P, Lefebvre O, Bellissent-Waydelich A, Olsen J, Orian-Rousseau V, De Arcangelis A. The laminins: Role in intestinal morphogenesis and differentiation. Ann NY Acad Sci 1998;859:46-64.
47. Bennett MV, Barrio LC, Bargiello TA, Spray DC, Hertzberg E, Saez JC. Gap junctions: New tools, new answers, new questions. Neuron 1991;6(3):305-320.
48. Yamasaki H, Naus CC. Role of connexin genes in growth control. Carcinogenesis 1996;17(6):1199-1213.
49. Lin JH, Takano T, Cotrina ML, et al. Connexin 43 enhances the adhesivity and mediates the invasion of malignant glioma cells. J Neurosci 2002;22(11):4302-4311.
50. Carystinos GD, Kandouz M, Alaoui-Jamali MA, Batist G. Unexpected induction of the human connexin 43 promoter by the ras signaling pathway is mediated by a novel putative promoter sequence. Mol Pharmacol 2003;63(4):821-831.
51. Shore L, McLean P, Gilmour SK, Hodgins MB, Finbow ME. Polyamines regulate gap junction communication in connexin 43-expressing cells. Biochem J 2001;357(Pt. 2):489-495.
52. Ueki S, Takagi J, Saito Y. Dual functions of transglutaminase in novel cell adhesion. J Cell Sci 1996;109(Pt. 11):2727-2735.
53. McCormack SA, Johnson LR. Role of polyamines in gastrointestinal mucosal growth. Am J Physiol 1991;260(6 Pt. 1): G795-G806.
54. Wang JY, Viar MJ, Johnson LR. Regulation of transglutaminase activity by polyamines in the gastrointestinal mucosa of rats. Proc Soc Exp Biol Med 1994;205(1):20-28.
55. Wang JY, Viar MJ, Li J, Shi HJ, Patel AR, Johnson LR. Differences in transglutaminase mRNA after polyamine depletion in two cell lines. Am J Physiol 1998;274(2 Pt. 1):C522-C530.
56. Parker MT, Gerner EW. Polyamine-mediated post-transcriptional regulation of COX-2. Biochimie 2002;84(8):815-819.
57. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: Structure, function, and association to disease. Endocr Rev 2001;22(2):184-204.
58. Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 1996;2(5):624-636.
59. Little SP, Dixon EP, Norris F, et al. Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain. J Biol Chem 1997;272(40): 25135-25142.
60. Petraki CD, Karavana VN, Skoufogiannis PT, et al. The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. J Histochem Cytochem 2001;49(11):1431-1441.